Novoclem announces CEO Anne Whitaker to present at the Biotech Showcase™ Annual Conference on Wednesday, January 10, 2018

DURHAM, N.C., Jan. 4, 2018 /PRNewswire/ -- Novoclem Therapeutics, a preclinical-stage pharmaceutical company focused on helping people who suffer from severe respiratory diseases to breathe better and live life more fully, today announced that it will present at Biotech Showcase™ 2018, to be held January 8^th –10^th at the Hilton San Francisco Union Square.

Date: January 10, 2018
Time: 2:00PM PST
Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA
Room: Yosemite B
Presenter: Anne Whitaker, CEO & President

About Biotech Showcase 2018
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

About Novoclem Therapeutics, Inc.
Novoclem Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, is initially focused on developing a nitric oxide based treatment for people living with cystic fibrosis and infected with Pseudomonas aeruginosa. The company anticipates submitting an Investigational New Drug application and initiating First in Human clinical trials in 2018. More info available at www.novoclem.com.   

About KNOW Bio LLC
KNOW Bio, LLC, is a life science company committed to improving and extending people's lives by advancing the development and commercialization of its drug and device pipeline through wholly or majority owned subsidiary companies.  Each subsidiary is focused on a specific therapeutic application where nitric oxide provides meaningful health benefit.

Forward-looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.  Actual results might differ materially from those explicit or implicit in the forward-looking statements.  Important factors that could cause actual results to differ materially include:  risks associated with the drug development process; reliance on key personnel; the early stage of our business; competition; and other risks described in other Company press releases and presentations.  KNOW Bio and Novoclem Therapeutics assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Media Contact:
Darlene Dendy
1-919-270-5789
[email protected] 

SOURCE Novoclem Therapeutics, Inc.

Related Links

http://www.novoclem.com